Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis.

The goal of this study was to explore the association between changes in B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) plasma levels and risk of hospital admission for heart failure (HF) worsening in patients with chronic HF. The relationship between BNP and NT-proBNP plasma levels and risk of cardiovascular events in patients with chronic HF has been previously demonstrated. However, it is unclear whether changes in BNP and NT-proBNP levels predict morbidity in patients with chronic HF. The MEDLINE, Cochrane, ISI Web of Science, and SCOPUS databases were searched for papers about HF treatment up to August 2013. Randomized trials enrolling patients with systolic HF, assessing BNP and/or NT-proBNP at baseline and at end of follow-up, and reporting hospital stay for HF were included in the analysis. Meta-regression analysis was performed to test the relationship between BNP and NT-proBNP changes and the clinical endpoint. Sensitivity analysis was performed to assess the influence of baseline variables on results. Egger's linear regression was used to assess publication bias. Nineteen trials enrolling 12,891 participants were included. The median follow-up was 9.5 months (interquartile range: 6 to 18 months), and 22% of patients were women. Active treatments significantly reduced the risk of hospital stay for HF worsening. In meta-regression analysis, changes in BNP and NT-proBNP were significantly associated with risk of hospital stay for HF worsening. Results were confirmed by using sensitivity analysis. No publication bias was detected. In patients with HF, reduction of BNP or NT-proBNP levels was associated with reduced risk of hospital stay for HF worsening.

Savarese G ，Musella F ，D'Amore C ，Vassallo E ，Losco T ，Gambardella F ，Cecere M ，Petraglia L ，Pagano G ，Fimiani L ，Rengo G ，Leosco D ，Trimarco B ，Perrone-Filardi P ... -  《-》

Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.

Sanders-van Wijk S ，Maeder MT ，Nietlispach F ，Rickli H ，Estlinbaum W ，Erne P ，Rickenbacher P ，Peter M ，Pfisterer MP ，Brunner-La Rocca HP ，TIME-CHF Investigators ... -  《-》

The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors.

Suzuki S ，Sugiyama S 《-》

Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.

Rørth R ，Jhund PS ，Yilmaz MB ，Kristensen SL ，Welsh P ，Desai AS ，Køber L ，Prescott MF ，Rouleau JL ，Solomon SD ，Swedberg K ，Zile MR ，Packer M ，McMurray JJV ... -  《-》

Validation of the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) heart failure risk score and the effect of adding natriuretic peptide for predicting mortality after discharge in hospitalized patients with heart failure.

Khanam SS ，Choi E ，Son JW ，Lee JW ，Youn YJ ，Yoon J ，Lee SH ，Kim JY ，Ahn SG ，Ahn MS ，Kang SM ，Baek SH ，Jeon ES ，Kim JJ ，Cho MC ，Chae SC ，Oh BH ，Choi DJ ，Yoo BS ... -  《PLoS One》